Pfizer Inc. (PFE)
Pfizer Inc.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Pfizer reads as neutral right now, with no clear lean either way.
- What's working
- Its price has held up well, trading above its recent averages.
- Worth watching
- Sales and profits grew slower over the past year than at most other healthcare companies, or shrank.
Analyst price target
~12-month · 26 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 75,000
- Headquarters
- New York, NY
Similar stocks
What’s behind the score
Valuation
P/E 38.9 — lower than 36% of Healthcare peers
P/B 2.0 — lower than 82% of Healthcare peers
P/S 2.6 — lower than 67% of Healthcare peers
EV/EBITDA 8.7 — lower than 87% of Healthcare peers
EV/Revenue 3.5 — lower than 67% of Healthcare peers
FCF yield 7.4% — higher than 93% of Healthcare peers
Profitability & quality
Gross margin 74.7% — higher than 83% of Healthcare peers
Operating margin 27.9% — higher than 67% of Healthcare peers
Net margin 6.8% — higher than 33% of Healthcare peers
ROE 5.0% — higher than 15% of Healthcare peers
ROA 5.8% — higher than 48% of Healthcare peers
Free cash flow is 288% of reported net income
Financial health
Debt/equity 0.7 — lower than 33% of Healthcare peers
Current ratio 1.27 — higher than 34% of Healthcare peers
Quick ratio 0.85 — higher than 45% of Healthcare peers
Cash/debt 0.18 — higher than 48% of Healthcare peers
Debt/EBITDA 2.50 — lower than 41% of Healthcare peers
Growth
Revenue growth 2.6% YoY — higher than 13% of Healthcare peers
Ownership & investor activity
Payout ratio 226.3% — atypical vs Healthcare peers
Net insider buying, +1.9% of insider shares
Institutions net sold, -15.7% of shares held
Insiders hold 0.1% of shares outstanding
2.6% of float sold short
Momentum
Above its 50- & 200-day averages
95% of the way from its 52-week low to high